NCT00847262

Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes

Hypertension With Obesity Trial: Diabetes Mellitus Branch

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Third Military Medical University · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Recent studies have shown that obese people are more prone to high blood pressure. With the co-existence of obesity, hypertension and diabetes, patients were more susceptible to hyperlipidemia, coronary and cerebral atherosclerosis and peripheral vascular disease. Abdominal obesity has often accompanied by substantial accumulation of visceral fat, which increased secretion of many inflammatory mediators, cytokines and adipocytokines and played an important role in cardiovascular and metabolic disease. Some reports had shown that angiotensin II receptor blockers (ARB) may improve metabolic profiles in patients with diabetes or metabolic syndrome, in addition to its hypotensive effect. It has been reported that some ARB, such as telmisartan and candesartan, can prevent weight gain and high-fat-induced obesity in experimental animals. However, whether telmisartan intervention on improvement of fat deposition and other related metabolic profiles is better than a CCB drugs (amlodipine) in those obese hypertensive patients with diabetes, was still unknown.

Conditions

• Hypertension
• Obesity
• Diabetes

Interventions

Type	Name	Description
DRUG	Temisartan	Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
DRUG	Amlodipine	Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day

Timeline

• Start date: 2008-06-01
• Primary completion: 2008-12-01
• Completion: 2009-06-01
• First posted: 2009-02-19
• Last updated: 2013-12-17

Locations

1 site across 1 country: China